Li Tao, PhD, discusses early US uptake of twice-yearly lenacapavir, faster prescription-to-injection timelines, and how ACA coverage milestones tracked with zero cost sharing and HIV diagnoses.
|Videos|August 5, 2021
The Modern HIV PrEP Options and Care Teams Are Evolving
Author(s)Kevin Kunzmann
Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.
Advertisement
The goals for
In the first segment of an interview with Contagion, David Koren, MPH, BCPS, Clinical Pharmacist Specialist in ID & HIV at Temple University Hospital, discussed the current administration strategies and research in place to combat a national decrease in PrEP prescriptions.
What’s needed, Koren stressed, is a prioritization of direct HIV-risk prescription access.
“In order for that to be able to happen, we just need more members of the care team,” Koren explained. “And I’d like to say that really has evolved to include pharmacists in a really meaningful way lately.”
The initiation of prescribing at the pharmacy level leads to the concept of “de-medicalizing PrEP,” Koren explained, and allowing for community-level access.
Along the way, new research is seeking to innovate the availability of PrEP options to include longer dose durations and different methods of delivery—details which emphasize the desire for patient-specific interests.
“Choice is king, especially when we’re asking people to take a medication for an infection they don’t even have,” Koren said. “People are going to come to the table with their own wants and needs.”
Advertisement
Related to this article
Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Advertisement
Advertisement